PLUS THERAPEUTICS, INC. Cash Flow Statement
PSTV|10 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
PLUS THERAPEUTICS, INC. used $11M in operating cash flow and negative free cash flow of $11M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.46 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$13.0M | -$13.3M | -$22.7M | -$22.0M | -$18.7M | -$26.2M | -$32.3M | -$32.5M | -$27.5M | -$23.2M |
| Depreciation & Amortization | $872.0K | $628.0K | $2.2M | $1.2M | $1.1M | $1.6M | $933.0K | $855.0K | $931.0K | $1.7M |
| Operating Cash Flow | -$10.6M | -$12.9M | -$18.1M | -$19.5M | -$20.5M | -$34.6M | -$32.2M | -$35.3M | -$23.6M | -$23.8M |
| Capital Expenditures | $146.0K | $160.0K | - | $67.0K | $611.0K | $519.0K | $1.2M | $560.0K | $610.0K | $221.0K |
| Free Cash Flow | -$10.7M | -$13.0M | - | -$19.6M | -$21.1M | -$35.1M | -$33.4M | -$35.9M | -$24.2M | -$24.0M |
| Share Buybacks | $374.0K | $126.0K | - | - | - | - | - | - | - | - |
| FCF Margin | -183.7% | -264.8% | - | -421.0% | -435.7% | -492.6% | -383.5% | -449.5% | -293.0% | -411.7% |